{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T04:49:50Z","timestamp":1683866990588},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s11926-006-0014-6","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T11:14:46Z","timestamp":1180782886000},"page":"303-311","source":"Crossref","is-referenced-by-count":5,"title":["Wegener\u2019s granulomatosis: Is biologic therapy useful?"],"prefix":"10.1007","volume":"8","author":[{"given":"Pasha","family":"Sarraf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Friday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony M.","family":"Reginato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"14_CR1","first-page":"36","volume":"102","author":"F Wegener","year":"1939","unstructured":"Wegener F: Uber eine eigenartige rhinogene Granulomatose mit besonderer beteilig arteriensystems und der nieren [A unique rhinogenic granulomatosis with special involvement of the arterial system and the kidneys]. Beitr Pathol Anat allg Pathol 1939, 102:36\u201368.","journal-title":"Beitr Pathol Anat allg Pathol"},{"key":"14_CR2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00005792-199411000-00006","volume":"73","author":"GS Hoffman","year":"1994","unstructured":"Hoffman GS: \"Wegener\u2019s granulomatosis\": the path traveled since 1931. Medicine (Baltimore) 1994, 73:325\u2013329.","journal-title":"Medicine (Baltimore)"},{"key":"14_CR3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman GS, Kerr GS, Leavitt RY, et al.: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488\u2013498.","journal-title":"Ann Intern Med"},{"key":"14_CR4","first-page":"309","volume":"29","author":"NI Abdou","year":"2002","unstructured":"Abdou NI, Kullman GJ, Hoffman GS, et al.: Wegener\u2019s granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 2002, 29:309\u2013316.","journal-title":"J Rheumatol"},{"key":"14_CR5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","volume":"34","author":"EW Walton","year":"1958","unstructured":"Walton EW: Giant-cell granuloma of the respiratory tract (Wegener\u2019s granulomatosis). Br Med J 1958, 34:265\u2013270.","journal-title":"Br Med J"},{"key":"14_CR6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-67-2-393","volume":"67","author":"D Hollander","year":"1967","unstructured":"Hollander D, Manning RT: The use of alkylating agents in the treatment of Wegener\u2019s granulomatosis. Ann Intern Med 1967, 67:393\u2013398.","journal-title":"Ann Intern Med"},{"key":"14_CR7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","volume":"52","author":"AS Fauci","year":"1973","unstructured":"Fauci AS, Wolff SM: Wegener\u2019s granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973, 52:535\u2013561.","journal-title":"Medicine (Baltimore)"},{"key":"14_CR8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00004728-199705000-00021","volume":"21","author":"NA Courcoutsakis","year":"1997","unstructured":"Courcoutsakis NA, Langford CA, Sneller MC, et al.:Orbital involvement in Wegener granulomatosis: MR findings in 12 patients. J Comput Assist Tomogr 1997, 21:452\u2013458.","journal-title":"J Comput Assist Tomogr"},{"key":"14_CR9","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.1780391020","volume":"39","author":"CA Langford","year":"1996","unstructured":"Langford CA, Sneller MC, Hallahan CW, et al.: Clinical features and therapeutic management of subglottic stenosis in patients with Wegener\u2019s granulomatosis. Arthritis Rheum 1996, 39:1754\u20131760.","journal-title":"Arthritis Rheum"},{"key":"14_CR10","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/art.21117","volume":"52","author":"P Seo","year":"2005","unstructured":"Seo P, Min YI, Holbrook, et al.: Damage caused by Wegener\u2019s granulomatosis and its treatment: prospective data from the Wegener\u2019s Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005, 52:2168\u20132178.","journal-title":"Arthritis Rheum"},{"key":"14_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146239940500921X","volume":"7","author":"P Sarraf","year":"2005","unstructured":"Sarraf P, Sneller MC: Pathogenesis of Wegener\u2019s granulomatosis: current concepts. Expert Rev Mol Med 2005, 7:1\u201319.","journal-title":"Expert Rev Mol Med"},{"key":"14_CR12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/978-1-4757-9182-2_71","volume":"336","author":"GS Kerr","year":"1993","unstructured":"Kerr GS, Fleisher TA, Hallahan CW, et al.: Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener\u2019s granulomatosis. Adv Exp Med Biol 1993, 336:411\u2013414.","journal-title":"Adv Exp Med Biol"},{"key":"14_CR13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00002281-199305010-00004","volume":"5","author":"JL Niles","year":"1993","unstructured":"Niles JL: Value of tests for antineutrophil cytoplasmic autoantibodies in the diagnosis and treatment of vasculitis. Curr Opin Rheumatol 1993, 5:18\u201324.","journal-title":"Curr Opin Rheumatol"},{"key":"14_CR14","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O","volume":"43","author":"MM Boomsma","year":"2000","unstructured":"Boomsma MM, Stegeman CA, van der Leig, et al.:Prediction of relapses in Wegener\u2019s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000, 43:2025\u20132033.","journal-title":"Arthritis Rheum"},{"key":"14_CR15","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1073\/pnas.87.11.4115","volume":"87","author":"RJ Falk","year":"1990","unstructured":"Falk RJ, Terrell RS, Charles LA, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990, 87:4115\u20134119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14_CR16","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1681\/ASN.2005101048","volume":"17","author":"JC Jennette","year":"2006","unstructured":"Jennette JC, Xiao H, Falk RJ: Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2006, 17:1235\u20131242.","journal-title":"J Am Soc Nephrol"},{"key":"14_CR17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","volume":"110","author":"H Xiao","year":"2002","unstructured":"Xiao H, Heeringa P, Hu P, et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955\u2013963. This article describes the first animal model for tissue injury induced by myeloperoxidase-antineutrophil cytoplasmic autoantibodies. The clinical phenotype produced with the MPO knockout mice included some but not all of the clinical features of Wegener\u2019s granulomatosis.","journal-title":"J Clin Invest"},{"key":"14_CR18","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2004-01-0267","volume":"104","author":"H Pfister","year":"2004","unstructured":"Pfister H, Ollert M, Frohlich LF, et al.: Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004, 104:1411\u20131418. This review uses the strategy employed in the MPO-ANCA knockout mouse model to evaluate the role of PR3-ANCA immunopathogenesis.","journal-title":"Blood"},{"issue":"Suppl 2","key":"14_CR19","first-page":"SII40","volume":"69","author":"MC Sneller","year":"2002","unstructured":"Sneller MC: Granuloma formation, implications for the pathogenesis of vasculitis. Cleve Clin J Med 2002, 69(Suppl 2):SII40-SII43.","journal-title":"Cleve Clin J Med"},{"key":"14_CR20","first-page":"768","volume":"7","author":"PM Aries","year":"2005","unstructured":"Aries PM, Lamprecht P, Gross WL: Wegener\u2019s granulomatosis: a view from the granulomatous side of the disease. Isr Med Assoc J 2005, 7:768\u2013773.","journal-title":"Isr Med Assoc J"},{"key":"14_CR21","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.160.7.3602","volume":"160","author":"BR Ludviksson","year":"1998","unstructured":"Ludviksson BR, Sneller MC, Chua KS, et al.: Active Wegener\u2019s granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998, 160:3602\u20133609.","journal-title":"J Immunol"},{"key":"14_CR22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2249.2002.01801.x","volume":"128","author":"P Lamprecht","year":"2002","unstructured":"Lamprecht P, Kumanovics G, Mueller A, et al.: Elevated monocytic IL-12 and TNF-alpha production in Wegener\u2019s granulomatosis is normalized by cyclophosphamide and corticosteroid therapy. Clin Exp Immunol 2002, 128:181\u2013186.","journal-title":"Clin Exp Immunol"},{"key":"14_CR23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0954-6111(99)90093-8","volume":"93","author":"A Schnabel","year":"1999","unstructured":"Schnabel A, Reuter M, Gloeckner K, et al.: Bronchoalveolar lavage cell profiles in Wegener\u2019s granulomatosis. Respir Med 1999, 93:498\u2013506.","journal-title":"Respir Med"},{"key":"14_CR24","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/S0002-9440(10)61118-2","volume":"160","author":"A Komocsi","year":"2002","unstructured":"Komocsi A, Lamprecht P, Csernok E, et al.: Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener\u2019s granulomatosis. Am J Pathol 2002, 160:1717\u20131724.","journal-title":"Am J Pathol"},{"key":"14_CR25","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/ki.1993.98","volume":"43","author":"IL Noronha","year":"1993","unstructured":"Noronha IL, Kruger C, Andrassy K, et al.: In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993, 43:682\u2013692.","journal-title":"Kidney Int"},{"key":"14_CR26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1365-2249.2001.01575.x","volume":"126","author":"K Steiner","year":"2001","unstructured":"Steiner K, Moosig F, Csernok E, et al.: Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener\u2019s granulomatosis. Clin Exp Immunol 2001, 126:143\u2013150.","journal-title":"Clin Exp Immunol"},{"key":"14_CR27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/thorax.56.10.751","volume":"56","author":"P Lamprecht","year":"2001","unstructured":"Lamprecht P, Moosig F, Csernok E, et al.: CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener\u2019s granulomatosis. Thorax 2001, 56:751\u2013757.","journal-title":"Thorax"},{"key":"14_CR28","doi-asserted-by":"crossref","unstructured":"Csernok E, Ai M, Gross WL, et al.: Wegener\u2019s autoantigen induces maturation of dendritic cells and licences them for Th1 priming via the protease-activated receptor-2 pathway. Blood 2006, Epub ahead of print. This paper elucidates the role of proteinase 3 in dendritic cell activation in Wegener\u2019s granulomatosis.","DOI":"10.1182\/blood-2005-05-1875"},{"key":"14_CR29","first-page":"177","volume":"46","author":"CA Langford","year":"2001","unstructured":"Langford CA, Sneller MC: Update on the diagnosis and treatment of Wegener\u2019s granulomatosis. Adv Intern Med 2001, 46:177\u2013206.","journal-title":"Adv Intern Med"},{"key":"14_CR30","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/art.1780380505","volume":"38","author":"MC Sneller","year":"1995","unstructured":"Sneller MC, Hoffman GS, Talar-Williams C, et al.: An analysis of forty-two Wegener\u2019s granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995, 38:608\u2013613.","journal-title":"Arthritis Rheum"},{"key":"14_CR31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/rheumatology\/keh009","volume":"43","author":"C Metzler","year":"2004","unstructured":"Metzler C, Fink C, Lamprecht P, et al.: Maintenance of remission with leflunomide in Wegener\u2019s granulomatosis. Rheumatology (Oxford) 2004, 43:315\u2013320. This report presents the first use of leflunomide for the maintenance of remission in 20 patients with Wegener\u2019s granulomatosis.","journal-title":"Rheumatology (Oxford)"},{"key":"14_CR32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/art.20240","volume":"51","author":"CA Langford","year":"2004","unstructured":"Langford CA, Talar-Williams C, Sneller MC: Mycophenolate mofetil for remission maintenance in the treatment of Wegener\u2019s granulomatosis. Arthritis Rheum 2004, 51:278\u2013283.","journal-title":"Arthritis Rheum"},{"key":"14_CR33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne D, Rasmussen N, Andrassy K, et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:36\u201344.","journal-title":"N Engl J Med"},{"key":"14_CR34","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/1529-0131(199912)42:12<2666::AID-ANR24>3.0.CO;2-E","volume":"42","author":"CA Langford","year":"1999","unstructured":"Langford CA, Talar-Williams C, Barron KS, Sneller MC: A staged approach to the treatment of Wegener\u2019s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999, 42:2666\u20132673.","journal-title":"Arthritis Rheum"},{"key":"14_CR35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0002-9343(03)00077-9","volume":"114","author":"CA Langford","year":"2003","unstructured":"Langford CA, Talar-Williams C, Barron KS, Sneller MC: Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener\u2019s granulomatosis: extended follow-up and rate of relapse. Am J Med 2003, 114:463\u2013469.","journal-title":"Am J Med"},{"key":"14_CR36","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"Groot K De","year":"2005","unstructured":"De Groot K, Rasmussen N, Bacon PA, et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:2461\u20132469. This is the first randomized controlled clinical trial demonstrating that methotrexate can replace cyclophosphamide in early systemic ANCA-associated vasculitis. The high relapse rate provides a rationale for maintenance therapy beyond 12 months.","journal-title":"Arthritis Rheum"},{"key":"14_CR37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"The Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","unstructured":"The Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med 2005, 352:351\u2013361. This article presents the first large, placebo-controlled clinical trial evaluating the use of anti-tumor necrosis factor agent in Wegener\u2019s granulomatosis. The trial was powered to study the efficacy of etanercept for maintenance therapy.","journal-title":"N Engl J Med"},{"key":"14_CR38","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","volume":"54","author":"JH Stone","year":"2006","unstructured":"Stone JH, Holbrook JT, Marriott MA, et al.: Solid malignancies among patients in the Wegener\u2019s granulomatosis etanercept trial. Arthritis Rheum 2006, 54:1608\u20131618.","journal-title":"Arthritis Rheum"},{"key":"14_CR39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ijc.10444","volume":"100","author":"A Knight","year":"2002","unstructured":"Knight A, Askling J, Ekbom A: Cancer incidence in a population-based cohort of patients with Wegener\u2019s granulomatosis. Int J Cancer 2002, 100:82\u201385.","journal-title":"Int J Cancer"},{"key":"14_CR40","first-page":"2115","volume":"31","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K: Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients. J Rheumatol 2004, 31:2115\u20132120.","journal-title":"J Rheumatol"},{"key":"14_CR41","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088\u20131094.","journal-title":"Gastroenterology"},{"key":"14_CR42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","volume":"124","author":"JP Utz","year":"2003","unstructured":"Utz JP, Limper AH, Kalra S, et al.: Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003, 124:177\u2013185.","journal-title":"Chest"},{"key":"14_CR43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med 2003, 348:601\u2013608.","journal-title":"N Engl J Med"},{"issue":"Suppl 1)","key":"14_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semarthrit.2005.01.001","volume":"345","author":"WF Rigby","year":"2005","unstructured":"Rigby WF: Distinct mechanisms of action of tumor necrosis factor antagonists: what are the clinical implications? Semin Arthritis Rheum 2005, 345 Suppl 1):1\u20132. This review discusses the distinct mechanisms of action of currently marketed anti-tumor necrosis factor drugs.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"14_CR45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.semarthrit.2005.01.003","volume":"34","author":"B Haraoui","year":"2005","unstructured":"Haraoui B: Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005, 34(5 Suppl 1):7\u201311.","journal-title":"Semin Arthritis Rheum"},{"key":"14_CR46","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","volume":"15","author":"A Booth","year":"2004","unstructured":"Booth A, Harper L, Hammad T, et al.: Prospective study of TNF\u03b1 blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004, 15:717\u2013721. This report presents the largest prospective trial evaluating the efficacy of infliximab as an adjunct to the standard therapy in patients with ANCA-associated vasculitis.","journal-title":"J Am Soc Nephrol"},{"key":"14_CR47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/ard.61.6.559","volume":"61","author":"AD Booth","year":"2002","unstructured":"Booth AD, Jefferson HJ, Ayliffe W, et al.: Safety and efficacy of TNF\u03b1 blockade in relapsing vasculitis [letter]. Ann Rheum Dis 2002, 61:559.","journal-title":"Ann Rheum Dis"},{"key":"14_CR48","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","volume":"41","author":"P Lamprecht","year":"2002","unstructured":"Lamprecht P, Voswinkel J, Lilienthal T, et al.: Effectiveness of TNF-\u03b1 blockade with infliximab in refractory Wegener\u2019s granulomatosis. Rheumatology (Oxford) 2002, 41:1303\u20131307.","journal-title":"Rheumatology (Oxford)"},{"key":"14_CR49","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","volume":"41","author":"P Bartolucci","year":"2002","unstructured":"Bartolucci P, Ramanoelina J, Cohen P, et al.: Efficacy of the anti-TNF-\u03b1 antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002, 41:1126\u20131132.","journal-title":"Rheumatology (Oxford)"},{"key":"14_CR50","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.autrev.2005.04.004","volume":"4","author":"F Perosa","year":"2005","unstructured":"Perosa F, Favoino E, Caragnano MA, et al.: CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005, 4:526\u2013531.","journal-title":"Autoimmun Rev"},{"key":"14_CR51","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","volume":"48","author":"G Cambridge","year":"2003","unstructured":"Cambridge G, Leandro MJ, Edwards JC, et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003, 48:2146\u20132154.","journal-title":"Arthritis Rheum"},{"key":"14_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.20717","volume":"52","author":"MC Sneller","year":"2005","unstructured":"Sneller MC: Rituximab and Wegener\u2019s granulomatosis: Are B cells a target in vasculitis treatment? Arthritis Rheum 2005, 52:1\u20135.","journal-title":"Arthritis Rheum"},{"key":"14_CR53","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572\u20132581.","journal-title":"N Engl J Med"},{"key":"14_CR54","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","volume":"46","author":"Vita S De","year":"2002","unstructured":"De Vita S, Zaja F, Sacco S, et al.: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002, 46:2029\u20132033.","journal-title":"Arthritis Rheum"},{"key":"14_CR55","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D, et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50:2580\u20132589.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"14_CR56","doi-asserted-by":"crossref","first-page":"ii13","DOI":"10.1093\/rheumatology\/keh618","volume":"44","author":"RJ Looney","year":"2005","unstructured":"Looney RJ: B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology (Oxford) 2005, 44(Suppl 2):ii13-ii17.","journal-title":"Rheumatology (Oxford)"},{"key":"14_CR57","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","volume":"173","author":"KA Keogh","year":"2006","unstructured":"Keogh KA, Ytterberg SR, Fervenza FC, et al.: Rituximab for refractory Wegener\u2019s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006, 173:180\u2013187.","journal-title":"Am J Respir Crit Care Med"},{"key":"14_CR58","doi-asserted-by":"crossref","unstructured":"Aries PM, Hellmich B, Both M, et al.: Lack of efficacy of rituximab in Wegener\u2019s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2005, Epub ahead of print.","DOI":"10.1136\/ard.2005.044420"},{"key":"14_CR59","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","volume":"257","author":"P Eriksson","year":"2005","unstructured":"Eriksson P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005, 257:540\u2013548.","journal-title":"J Intern Med"},{"key":"14_CR60","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","volume":"52","author":"KA Keogh","year":"2005","unstructured":"Keogh KA, Wylam ME, Stone JH, Specks U: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:262\u2013268. This is the first prospective trial on rituximab given in addition to standard therapy in patients with antibody-associated vasculitis. The efficacy of rituximab is difficult to interpret because of multiple co-medications. This trial provides insight on the effects of B-cell blockade on ANCA.","journal-title":"Arthritis Rheum"},{"key":"14_CR61","unstructured":"Rituximab for the treatment of Wegener\u2019s granulomatosis and microscopic polyangiitis. http:\/\/www.clinicaltrials.gov\/ct\/ show\/NCT00104299?order=2. Accessed June 3, 2006."},{"key":"14_CR62","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","volume":"124","author":"C Talar-Williams","year":"1996","unstructured":"Talar-Williams C, Hijazi YM, Walther MM, et al.:Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996, 124:477\u2013484.","journal-title":"Ann Intern Med"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-006-0014-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-006-0014-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-006-0014-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T04:22:36Z","timestamp":1683865356000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-006-0014-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["14"],"URL":"https:\/\/doi.org\/10.1007\/s11926-006-0014-6","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}